Observational study finds 46% lower risk of heart events in vaccinated individuals — Evidence Review

People with atherosclerotic heart disease who received the shingles vaccine experienced nearly a 50% reduction in serious heart-related events within a year, according to a large observational study from the University of California, Riverside. Existing research on other vaccines, such as influenza and pneumococcal vaccines, generally supports the conclusion that certain vaccinations can reduce the risk of major cardiovascular events in high-risk populations.

• The observed risk reduction in heart-related events after shingles vaccination is comparable to reductions seen with influenza and pneumococcal vaccines, reinforcing the broader potential for vaccines to confer cardioprotective effects beyond their primary targets 1 2 4 9 10.
• Multiple studies report that influenza vaccination reduces the risk of major adverse cardiovascular events, especially in individuals with prior acute coronary syndromes, and that pneumococcal vaccination also lowers risks of acute myocardial infarction and mortality, particularly in older adults 1 2 4 9 10.
• While most research focuses on influenza and pneumococcal vaccines, recent analyses also suggest COVID-19 vaccination may reduce acute and post-acute cardiac and thromboembolic complications, indicating a growing recognition of the cardiovascular benefits of various vaccines 5.

Study Overview and Key Findings

This study investigates whether the shingles (herpes zoster) vaccine provides additional protective benefits for individuals with atherosclerotic heart disease, a group at elevated risk for heart attacks and strokes. The research is timely, as growing evidence suggests that vaccines may have broader health impacts than previously understood, especially in populations vulnerable to cardiovascular events. In the context of ongoing concerns about vaccine hesitancy and misinformation, the findings may influence public health messaging and clinical recommendations for older adults and those with chronic heart conditions.

Property	Value
Organization	University of California, Riverside
Authors	Robert Nguyen, MD
Population	Adults with atherosclerotic heart disease
Sample Size	n=246,822
Methods	Observational Study
Outcome	Heart-related events, mortality, heart attack, stroke, heart failure
Results	Vaccinated individuals had 46% lower major cardiac event risk.

Literature Review: Related Studies

To contextualize these findings, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:

1. vaccine heart disease risk reduction
2. vaccination major cardiac events
3. cardiovascular outcomes vaccine efficacy

Summary Table of Topics and Key Findings

Topic	Key Findings
Do vaccines reduce cardiovascular event risk in high-risk populations?	- Influenza vaccination is associated with a significant reduction (34–45%) in major adverse cardiovascular events, particularly in patients with recent acute coronary syndrome 1 2 3 9 10. - Pneumococcal vaccination lowers the risk of acute myocardial infarction and all-cause mortality, especially in individuals aged 65 and older 4.
What mechanisms link infection, vaccination, and cardiovascular events?	- Infections such as influenza, herpes zoster, and COVID-19 can trigger acute cardiovascular events, including heart attack and stroke, through inflammatory and pro-thrombotic pathways 1 2 5. - Preventing these infections via vaccination may reduce the incidence of cardiovascular events by mitigating inflammation and clot formation 1 2 4 5.
Are there cardiac risks associated with vaccination?	- COVID-19 vaccines, particularly mRNA vaccines, have been associated with rare cases of myocarditis and pericarditis, mainly in younger males, though the absolute risk is low compared to the risk from infection 6 7 8. - Most reported cardiovascular adverse events after vaccination are rare and not clearly causally linked to vaccines; routine monitoring is recommended 8.
What is the duration and magnitude of vaccine-related cardiovascular protection?	- Benefits of vaccination, such as with influenza or shingles vaccines, may persist for several years, with reductions in cardiovascular events and mortality observed up to eight years post-vaccination 2 9 10. - The magnitude of risk reduction for cardiovascular events is substantial and comparable to established interventions like smoking cessation 1 2 10.

---

Do vaccines reduce cardiovascular event risk in high-risk populations?

The new study aligns with a robust body of research showing that vaccination—primarily for influenza and pneumococcus—lowers the risk of major adverse cardiovascular events in patients with cardiovascular disease. These reductions are especially pronounced in individuals with recent acute coronary syndromes or older adults, supporting the idea that vaccination is a valuable secondary prevention strategy in high-risk groups.

• Multiple meta-analyses demonstrate that influenza vaccination reduces the risk of cardiovascular events by approximately 34–45%, and this effect is greatest in those with recent acute coronary syndromes 1 2 3 9 10.
• Pneumococcal vaccination has been shown to decrease the risk of acute myocardial infarction and all-cause mortality, particularly in people aged 65 and older 4.
• Randomized controlled trials and observational studies consistently support the inclusion of influenza and pneumococcal vaccines in guidelines for secondary prevention of heart disease 2 10.
• The magnitude of benefit observed for the shingles vaccine in the new study is similar to or exceeds those reported for influenza and pneumococcal vaccines 1 2 4 10.

What mechanisms link infection, vaccination, and cardiovascular events?

Both the new study and prior research suggest that certain infections—such as influenza, herpes zoster (shingles), and COVID-19—can precipitate acute cardiovascular events through inflammatory and pro-thrombotic mechanisms. Vaccination may interrupt this pathway by preventing infection, thereby reducing the risk of downstream cardiovascular complications.

• Influenza infection is associated with increased cardiovascular hospitalization and mortality; vaccination reduces this risk by preventing infection and subsequent inflammation 1 2.
• Herpes zoster infection has been linked to increased blood clot formation and higher rates of heart attack and stroke; preventing shingles may therefore lower the risk of these events 1 2 4.
• COVID-19 vaccination has been shown to reduce the risk of acute and post-acute cardiac and thromboembolic events following infection 5.
• Vaccines may provide indirect cardiovascular protection by lowering systemic inflammation and preventing infection-triggered vascular events 1 2 4 5.

Are there cardiac risks associated with vaccination?

Although rare cardiac complications have been reported following some vaccinations—most notably mRNA COVID-19 vaccines in younger males—the absolute risk remains low, and the risk of cardiac complications from the infections themselves is generally much higher. Most cardiovascular adverse events following vaccination do not appear to be causally linked, and the overall benefit-risk profile of vaccination remains strongly positive.

• Myocarditis and pericarditis have been observed at low rates after mRNA COVID-19 vaccination, primarily in young males, but these events are far less frequent than those observed after SARS-CoV-2 infection 6 7.
• The majority of cardiovascular adverse events reported after COVID-19 vaccination are mild, self-limiting, and not clearly attributable to the vaccine itself 7 8.
• Monitoring for rare but serious side effects remains important, but current evidence does not suggest that these outweigh the substantial cardiovascular benefits of vaccination 6 7 8.
• For vaccines like influenza and shingles, serious cardiovascular adverse events are exceedingly rare 1 2 4.

What is the duration and magnitude of vaccine-related cardiovascular protection?

The protective effects of vaccines against cardiovascular events can last for several years, though the duration may vary by vaccine type and population. The magnitude of risk reduction is comparable to, or even greater than, other established interventions for secondary prevention in cardiovascular disease.

• Influenza and shingles vaccination have been associated with risk reductions for cardiovascular events that persist for up to eight years in some studies 2 9 10.
• The observed reductions in major adverse cardiac events and mortality are substantial, sometimes approaching or exceeding those seen with lifestyle modifications like smoking cessation 1 2 10.
• The new study’s finding of a 46% reduction in major cardiac events after shingles vaccination is consistent with, and in some cases greater than, the effect sizes reported for influenza and pneumococcal vaccines 1 2 4 10.
• Ongoing research is needed to determine the optimal frequency and duration of vaccination to maintain these protective effects 2 9 10.

Future Research Questions

While the existing evidence base suggests that vaccination can reduce cardiovascular risk in high-risk populations, further research is warranted to address remaining uncertainties. Key areas for future investigation include the mechanisms underlying vaccine-associated cardioprotection, long-term outcomes, and strategies to optimize vaccination coverage in vulnerable groups.

Research Question	Relevance
What are the long-term effects of shingles vaccination on cardiovascular events?	The current study evaluated outcomes within one year; longer-term follow-up is needed to determine if the observed risk reduction persists over time 2 9 10.
How do different vaccine types (e.g. Shingrix vs Zostavax) compare in reducing cardiovascular risk?	Comparative effectiveness studies could clarify whether newer vaccine formulations provide greater or more durable cardiovascular benefits 1 2 4.
What mechanisms underlie the cardioprotective effects of vaccination?	Understanding the biological pathways could inform vaccine development and identify additional therapeutic targets for cardiovascular disease prevention 1 2 5.
Do repeated or booster vaccinations further reduce cardiovascular risk in high-risk populations?	It is unclear whether ongoing vaccination provides additive protection or if there is a plateau effect; prospective studies could address this question 2 10.
How do sociodemographic factors and health behaviors influence the relationship between vaccination and cardiovascular outcomes?	Understanding the role of confounding by healthy user bias and structural factors may improve the interpretation of observational data and guide equitable vaccination strategies 2 4.